For decades, sub-Saharan Africa has borne the heaviest burden of the global HIV epidemic while importing nearly 70 per cent of its finished medicines and almost all of its active pharmaceutical ingredients from overseas. That dependency creates a fragile house of cards. When foreign aid drops or global supply chains choke, local health systems suffer immediately.
Things are starting to shift. Kenya, Uganda, and South Africa are stepping up to manufacture next-generation HIV prevention medicines locally. Backed by global health agencies like Unitaid, regional manufacturers are preparing to produce groundbreaking options like alimatravir—a once-monthly oral pre-exposure prophylaxis (PrEP) pill currently in Phase III clinical trials—right on home soil.
Breaking the Cycle of Foreign Import Dependence
Importing drugs from thousands of miles away sounds simple until a crisis hits. Supply bottlenecks, shipping delays, and shifting foreign aid priorities leave millions vulnerable. Recent funding cuts from major international donors have shuttered treatment centres and disrupted prevention rollouts across multiple countries.
Local manufacturing changes the math. By building regional production capacity through programs like MedSuRe Africa, countries can secure steady supplies without waiting months for overseas cargo.
"African countries should not wait years for novel medicines originated elsewhere."
— Stavros Nicolaou, Aspen Pharma Group📖 Related: full body red light
Institutions like Uganda's Quality Chemical Industries Limited (Qcil), Kenya's Universal Corporation Limited (UCL), and South Africa's Aspen Pharmacare already have established track records producing quality-assured treatments for HIV and malaria. Bringing them into the fold for next-generation products means the continent can manufacture what it needs, where it is needed.
The Promise of Next-Generation Prevention
Daily pills work, but consistency is hard. Life gets busy, stigma interferes, and routines break down. That is why medical innovation has shifted toward long-acting solutions that fit real human lives.
Take lenacapavir, a twice-yearly injectable antiretroviral that offers powerful protection with minimal friction. Countries across Africa have begun rolling it out, though initial demand has quickly outpaced available supply.
Adding once-monthly oral options like alimatravir to the pipeline gives people choices. Some prefer a monthly pill; others want an injection every six months. Giving local manufacturers early technical and regulatory support means these options can reach communities faster and at a lower cost once regulatory hurdles are cleared.
What Needs to Happen Next
Building a factory is only half the battle. Public health experts point out that true self-reliance requires four core pillars:
- Sustained Investment: Upfront capital for technical expertise and plant upgrades.
- Regulatory Support: Accelerated local approvals without compromising safety standards.
- Guaranteed Markets: Predictable public procurement so factories can run at scale.
- Robust Diagnostics: Ensuring local testing infrastructure keeps pace with drug distribution.
Local production will not fix every systemic funding gap overnight. It builds a resilient foundation that protects public health against future global shocks. Africa is ready to make its own medicine. The support systems are finally catching up. Stop waiting for overseas relief and look to regional manufacturing to secure the future.
